{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:34:17Z","timestamp":1794724457766,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The gain-of-function\n                    <jats:italic>MUC5B<\/jats:italic>\n                    promoter variant rs35705950 is the dominant risk factor for developing idiopathic pulmonary fibrosis (IPF). Here we show in humans that\n                    <jats:italic>MUC5B<\/jats:italic>\n                    , a mucin thought to be restricted to conducting airways, is co-expressed with surfactant protein C (\n                    <jats:italic>SFTPC<\/jats:italic>\n                    ) in type 2 alveolar epithelia and in epithelial cells lining honeycomb cysts, indicating that cell types involved in lung fibrosis in distal airspace express\n                    <jats:italic>MUC5B<\/jats:italic>\n                    . In mice, we demonstrate that Muc5b concentration in bronchoalveolar epithelia is related to impaired mucociliary clearance (MCC) and to the extent and persistence of bleomycin-induced lung fibrosis. We also establish the ability of the mucolytic agent P-2119 to restore MCC and to suppress bleomycin-induced lung fibrosis in the setting of Muc5b overexpression. Our findings suggest that mucociliary dysfunction might play a causative role in bleomycin-induced pulmonary fibrosis in mice overexpressing Muc5b, and that MUC5B in distal airspaces is a potential therapeutic target in humans with IPF.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-07768-9","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T05:56:28Z","timestamp":1544594188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":243,"title":["Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Laura A.","family":"Hancock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne E.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Dobrinskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alani","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9270-777X","authenticated-orcid":false,"given":"David B.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Kissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0594","authenticated-orcid":false,"given":"Matthew R.","family":"Markovetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Grove Villalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo J.","family":"Tearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin I.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Thelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana V.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6743-8443","authenticated-orcid":false,"given":"David A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"7768_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care. Med. 198, e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"7768_CR2","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr.","year":"2014","unstructured":"King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"7768_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","volume":"108","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir. Med. 108, 1023\u20131030 (2014).","journal-title":"Respir. Med."},{"key":"7768_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"MA Seibold","year":"2011","unstructured":"Seibold, M. A. et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364, 1503\u20131512 (2011).","journal-title":"N. Engl. J. Med."},{"key":"7768_CR5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1152\/physrev.00004.2016","volume":"96","author":"CM Evans","year":"2016","unstructured":"Evans, C. M. et al. Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways. Physiol. Rev. 96, 1567\u20131591 (2016).","journal-title":"Physiol. Rev."},{"key":"7768_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00010.2005","volume":"86","author":"MC Rose","year":"2006","unstructured":"Rose, M. C. & Voynow, J. A. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol. Rev. 86, 245\u2013278 (2006).","journal-title":"Physiol. Rev."},{"key":"7768_CR7","doi-asserted-by":"publisher","first-page":"e58658","DOI":"10.1371\/journal.pone.0058658","volume":"8","author":"MA Seibold","year":"2013","unstructured":"Seibold, M. A. et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS ONE 8, e58658 (2013).","journal-title":"PLoS ONE"},{"key":"7768_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1164\/rccm.201509-1872LE","volume":"193","author":"Y Nakano","year":"2016","unstructured":"Nakano, Y. et al. MUC5B promoter variant rs35705950 affects MUC5B expression in the distal airways in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 193, 464\u2013466 (2016).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"7768_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1165\/rcmb.2017-0046OC","volume":"57","author":"BA Helling","year":"2017","unstructured":"Helling, B. A. et al. Regulation of MUC5B expression in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 57, 91\u201399 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"7768_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature12807","volume":"505","author":"MG Roy","year":"2014","unstructured":"Roy, M. G. et al. Muc5b is required for airway defence. Nature 505, 412\u2013416 (2014).","journal-title":"Nature"},{"key":"7768_CR11","doi-asserted-by":"publisher","first-page":"L442","DOI":"10.1152\/ajplung.00026.2010","volume":"299","author":"AL Degryse","year":"2010","unstructured":"Degryse, A. L. et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 299, L442\u2013L452 (2010).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"7768_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1126\/science.1223012","volume":"337","author":"B Button","year":"2012","unstructured":"Button, B. et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337, 937\u2013941 (2012).","journal-title":"Science"},{"key":"7768_CR13","doi-asserted-by":"publisher","first-page":"e39809","DOI":"10.1371\/journal.pone.0039809","volume":"7","author":"PA Sloane","year":"2012","unstructured":"Sloane, P. A. et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS ONE 7, e39809 (2012).","journal-title":"PLoS ONE"},{"key":"7768_CR14","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1364\/BOE.7.002494","volume":"7","author":"KK Chu","year":"2016","unstructured":"Chu, K. K. et al. In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography. Biomed. Opt. Express 7, 2494\u20132505 (2016).","journal-title":"Biomed. Opt. Express"},{"key":"7768_CR15","doi-asserted-by":"publisher","first-page":"e91702","DOI":"10.1172\/jci.insight.91702","volume":"2","author":"GM Solomon","year":"2017","unstructured":"Solomon, G. M. et al. Assessment of ciliary phenotype in primary ciliary dyskinesia by micro-optical coherence tomography. JCI Insight 2, e91702 (2017).","journal-title":"JCI Insight"},{"key":"7768_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1164\/rccm.201404-0670OC","volume":"190","author":"SE Birket","year":"2014","unstructured":"Birket, S. E. et al. A functional anatomic defect of the cystic fibrosis airway. Am. J. Respir. Crit. Care. Med. 190, 421\u2013432 (2014).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"7768_CR17","unstructured":"Johnson M. R., Thelin W. R. Novel monothiol mucolytic agents. Patent WO2016123335A1 (2016)."},{"key":"7768_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","volume":"40","author":"A Moeller","year":"2008","unstructured":"Moeller, A., Ask, K., Warburton, D., Gauldie, J. & Kolb, M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40, 362\u2013382 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"7768_CR19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMra0910061","volume":"363","author":"JV Fahy","year":"2010","unstructured":"Fahy, J. V. & Dickey, B. F. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233\u20132247 (2010).","journal-title":"N. Engl. J. Med."},{"key":"7768_CR20","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1513\/AnnalsATS.201512-796ED","volume":"13","author":"B Button","year":"2016","unstructured":"Button, B., Anderson, W. H. & Boucher, R. C. Mucus hyperconcentration as a unifying aspect of the chronic bronchitic phenotype. Ann. Am. Thorac. Soc. 13, S156\u2013S162 (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"7768_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7281","volume":"6","author":"CM Evans","year":"2015","unstructured":"Evans, C. M. et al. The polymeric mucin Muc5ac is required for allergic airway hyperreactivity. Nat. Commun. 6, 6281 (2015).","journal-title":"Nat. Commun."},{"key":"7768_CR22","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1001\/jama.2013.5827","volume":"309","author":"AL Peljto","year":"2013","unstructured":"Peljto, A. L. et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309, 2232\u20132239 (2013).","journal-title":"JAMA"},{"key":"7768_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1164\/rccm.201403-0541OC","volume":"190","author":"PL Molyneaux","year":"2014","unstructured":"Molyneaux, P. L. et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 190, 906\u2013913 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"7768_CR24","doi-asserted-by":"crossref","unstructured":"Fernandez-Blanco, J. A., et al. Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs. JCI Iinsight 3,\u00a0906\u2013913 (2018).","DOI":"10.1172\/jci.insight.120994"},{"key":"7768_CR25","doi-asserted-by":"crossref","unstructured":"Bauer, A. K., et al. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight 3,\u00a0120941 (2018).","DOI":"10.1172\/jci.insight.120941"},{"key":"7768_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/mi.2017.29","volume":"10","author":"A Livraghi-Butrico","year":"2017","unstructured":"Livraghi-Butrico, A. et al. Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol. 10, 829 (2017).","journal-title":"Mucosal Immunol."},{"key":"7768_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1165\/rcmb.2004-0060OC","volume":"31","author":"CM Evans","year":"2004","unstructured":"Evans, C. M. et al. Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. Am. J. Respir. Cell Mol. Biol. 31, 382\u2013394 (2004).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"7768_CR28","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1113\/jphysiol.2007.149310","volume":"586","author":"Y Zhu","year":"2008","unstructured":"Zhu, Y. et al. Munc13-2-\/- baseline secretion defect reveals source of oligomeric mucins in mouse airways. J. Physiol. 586, 1977\u20131992 (2008).","journal-title":"J. Physiol."},{"key":"7768_CR29","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/S0002-9440(10)64338-6","volume":"162","author":"JR Reader","year":"2003","unstructured":"Reader, J. R. et al. Pathogenesis of mucous cell metaplasia in a murine asthma model. Am. J. Pathol. 162, 2069\u20132078 (2003).","journal-title":"Am. J. Pathol."},{"key":"7768_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1165\/rcmb.2016-0226OC","volume":"56","author":"SV Raju","year":"2017","unstructured":"Raju, S. V. et al. The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke. Am. J. Respir. Cell Mol. Biol. 56, 99\u2013108 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"7768_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJMe1014191","volume":"364","author":"RC Boucher","year":"2011","unstructured":"Boucher, R. C. Idiopathic pulmonary fibrosis\u2013a sticky business. N. Engl. J. Med. 364, 1560\u20131561 (2011).","journal-title":"N. Engl. J. Med."},{"key":"7768_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/01902148.2014.979516","volume":"41","author":"JD Williamson","year":"2015","unstructured":"Williamson, J. D., Sadofsky, L. R. & Hart, S. P. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp. Lung Res. 41, 57\u201373 (2015).","journal-title":"Exp. Lung Res."},{"key":"7768_CR33","doi-asserted-by":"publisher","first-page":"e59348","DOI":"10.1371\/journal.pone.0059348","volume":"8","author":"R Peng","year":"2013","unstructured":"Peng, R. et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for \u201cactive\u201d disease. PLoS ONE 8, e59348 (2013).","journal-title":"PLoS ONE"},{"key":"7768_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/thoraxjnl-2012-202943","volume":"68","author":"IV Yang","year":"2013","unstructured":"Yang, I. V. et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68, 1114\u20131121 (2013).","journal-title":"Thorax"},{"key":"7768_CR35","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1371\/journal.pmed.0020251","volume":"2","author":"A Pardo","year":"2005","unstructured":"Pardo, A. et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2, e251 (2005).","journal-title":"PLoS Med."},{"key":"7768_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1165\/rcmb.2012-0083OC","volume":"48","author":"SA Gharib","year":"2013","unstructured":"Gharib, S. A. et al. Matrix metalloproteinase-7 coordinates airway epithelial injury response and differentiation of ciliated cells. Am. J. Respir. Cell Mol. Biol. 48, 390\u2013396 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"7768_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1164\/rccm.201412-2230OC","volume":"192","author":"WH Anderson","year":"2015","unstructured":"Anderson, W. H. et al. The relationship of mucus concentration (Hydration) to mucus osmotic pressure and transport in chronic bronchitis. Am. J. Respir. Crit. Care. Med. 192, 182\u2013190 (2015).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"7768_CR38","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1056\/NEJMoa1216076","volume":"368","author":"GM Hunninghake","year":"2013","unstructured":"Hunninghake, G. M. et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N. Engl. J. Med. 368, 2192\u20132200 (2013).","journal-title":"N. Engl. J. Med."},{"key":"7768_CR39","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1164\/rccm.201512-2523OC","volume":"194","author":"T Araki","year":"2016","unstructured":"Araki, T. et al. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am. J. Respir. Crit. Care Med. 194, 1514\u20131522 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"7768_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1164\/rccm.201406-1162OC","volume":"191","author":"JA Kropski","year":"2015","unstructured":"Kropski, J. A. et al. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am. J. Respir. Crit. Care Med. 191, 417\u2013426 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"7768_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1165\/rcmb.2007-0340OC","volume":"39","author":"JW Voltz","year":"2008","unstructured":"Voltz, J. W. et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 39, 45\u201352 (2008).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"7768_CR42","doi-asserted-by":"publisher","first-page":"L510","DOI":"10.1152\/ajplung.00122.2011","volume":"301","author":"EF Redente","year":"2011","unstructured":"Redente, E. F. et al. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 301, L510\u2013L518 (2011).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"7768_CR43","doi-asserted-by":"publisher","first-page":"L15","DOI":"10.1152\/ajplung.00429.2012","volume":"305","author":"M Ochs","year":"2013","unstructured":"Ochs, M. & Muhlfeld, C. Quantitative microscopy of the lung: a problem-based approach. Part 1: basic principles of lung stereology. Am. J. Physiol. Lung Cell Mol. Physiol. 305, L15\u2013L22 (2013).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"7768_CR44","doi-asserted-by":"publisher","first-page":"e54473","DOI":"10.1371\/journal.pone.0054473","volume":"8","author":"L Liu","year":"2013","unstructured":"Liu, L. et al. Method for quantitative study of airway functional microanatomy using micro-optical coherence tomography. PLoS ONE 8, e54473 (2013).","journal-title":"PLoS ONE"},{"key":"7768_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1006\/abio.1994.1290","volume":"220","author":"JC Han","year":"1994","unstructured":"Han, J. C. & Han, G. Y. A procedure for quantitative determination of tris(2-carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol. Anal. Biochem. 220, 5\u201310 (1994).","journal-title":"Anal. Biochem."},{"key":"7768_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1042\/bj3610537","volume":"361","author":"S Kirkham","year":"2002","unstructured":"Kirkham, S., Sheehan, J. K., Knight, D., Richardson, P. S. & Thornton, D. J. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem. J. 361, 537\u2013546 (2002).","journal-title":"Biochem. J."},{"key":"7768_CR47","first-page":"119","volume":"32","author":"DJ Thornton","year":"1994","unstructured":"Thornton, D. J., Carlstedt, I. & Sheehan, J. K. Identification of glycoproteins on nitrocellulose membranes and gels. Methods Mol. Biol. 32, 119\u2013128 (1994).","journal-title":"Methods Mol. Biol."},{"key":"7768_CR48","doi-asserted-by":"publisher","first-page":"e88198","DOI":"10.1172\/jci.insight.88198","volume":"1","author":"GA Duncan","year":"2016","unstructured":"Duncan, G. A. et al. Microstructural alterations of sputum in cystic fibrosis lung disease. JCI Insight 1, e88198 (2016).","journal-title":"JCI Insight"},{"key":"7768_CR49","doi-asserted-by":"publisher","first-page":"e87681","DOI":"10.1371\/journal.pone.0087681","volume":"9","author":"DB Hill","year":"2014","unstructured":"Hill, D. B. et al. A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease. PLoS ONE 9, e87681 (2014).","journal-title":"PLoS ONE"},{"key":"7768_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1465-9921-13-98","volume":"13","author":"J Seagrave","year":"2012","unstructured":"Seagrave, J., Albrecht, H. H., Hill, D. B., Rogers, D. F. & Solomon, G. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respir. Res. 13, 98 (2012).","journal-title":"Respir. Res."},{"key":"7768_CR51","doi-asserted-by":"publisher","first-page":"18131","DOI":"10.1073\/pnas.0606428103","volume":"103","author":"H Matsui","year":"2006","unstructured":"Matsui, H. et al. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc. Natl Acad. Sci. USA 103, 18131\u201318136 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7768_CR52","doi-asserted-by":"publisher","first-page":"15064","DOI":"10.1073\/pnas.0803124105","volume":"105","author":"ME Johansson","year":"2008","unstructured":"Johansson, M. E. et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl Acad. Sci. USA 105, 15064\u201315069 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07768-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07768-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07768-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T16:36:35Z","timestamp":1671554195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07768-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["7768"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-07768-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734655690.793554738","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"5 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.S. is the founder and chief scientific officer of Eleven P15, a company focused on the early diagnosis and treatment of pulmonary fibrosis. D.A.S. has patents awarded (US Patent no: 8,673,565) and submitted (US Patent application no: 62\/250,390, US Patent application no: 62\/525,087, and US Patent application no: 62\/525,088) for the treatment and diagnosis of fibrotic lung disease. D.E.G.V., M.E.V. and W.R.T. are employees of Parion Sciences. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5363"}}